SEC Charges Cassava Sciences, Two Former Executives for Misleading Claims About Alzheimer’s Clinical Trial - SEC.gov

SEC Charges Cassava Sciences, Two Former Executives for Misleading Claims About Alzheimer’s Clinical Trial  SEC.govCassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims  BloombergStocks to Watch: Cassava Sciences, Scholastic, MeridianLink  MarketWatchCassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines  STATAlzheimer’s Drug Developer Cassava Paying $40 Million to Settle Doctored Data Claims  The Wall Street Journal